@article{article_237849, title={Intestinal Perforation after Bevacizumab Treatment in Metastatic Colon Cancer: A Rare Case}, journal={Dicle Medical Journal}, volume={43}, year={2016}, DOI={10.5798/diclemedj.0921.2016.01.0661}, author={Çetin, Durmuş and Gündeş, Ebubekir and Aday, Ulaş and Çiyiltepe, Hüseyin and Değer, Kamuran and Duman, Mustafa}, keywords={Bevacizumab, ince barsak perforasyonu, metastatik kolorektal kanser}, abstract={<p>Bevacizumab is a monoclonal antibody which is targeting to vascular endothelial growth factor. It has been shown to be a promising drug on metastatic colorectal cancer and is combined with chemotherapeutic agents. One should be aware of serious complications even though bevacizumab is a well-tolerated drug. There are a few intestinal perforation cases that have been reported in the oncologic surgery literature related to the bevacizumab treatment. In this case report, we aimed to represent a 45 years old man who was diagnosed with intestinal perforation after bevacizumab treatment ten months after a metastatic colon cancer surgery. <br />Key words: Bevacizumab, intestinal perforation, metastatic colorectal cancer </p>}, number={1}, publisher={Dicle University}